Source: NETAG
Area: News
The North East Treatment Advisory Group (NETAG) has produced an updated appraisal of bevacizumab for the management of neovascular age-related macular degeneration and recommended bevacizumab 1.25 mg intravitreal injection as cost effective treatment option for this condition. The group was satisfied that the relative clinical efficacy and safety of bevacizumab for AMD had been adequately demonstrated.
It should be noted that bevacizumab is not licensed for any ophthalmic indication. Ranibizumab is licensed for wet age-related macular degeneration and there is NICE guidance available which supports ranibizumab in this indication.
The Group was concerned about the implications of using an unlicensed treatment where a licensed alternative treatment is currently used, and was mindful of concerns raised by clinicians regarding prescribing responsibilities and patient information. However, it was felt that these issues were not impossible to address and could be ...
Uncategorized